KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Accured Expenses: 2017-2024

Historic Change in Accured Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$1.5 million.

  • Aquestive Therapeutics' Change in Accured Expenses rose 117.82% to $118,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year increase of 21.46%. This contributed to the annual value of -$1.5 million for FY2024, which is 40.68% up from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Change in Accured Expenses is -$1.5 million, which was up 40.68% from -$2.5 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Change in Accured Expenses registered a high of $3.0 million during FY2020, and its lowest value of -$2.5 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is -$2.1 million, with a median of -$2.4 million in 2022.
  • Per our database at Business Quant, Aquestive Therapeutics' Change in Accured Expenses surged by 299.46% in 2020 and then slumped by 182.23% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Change in Accured Expenses (Yearly) stood at $3.0 million in 2020, then plummeted by 128.32% to -$844,000 in 2021, then plummeted by 182.23% to -$2.4 million in 2022, then declined by 5.58% to -$2.5 million in 2023, then spiked by 40.68% to -$1.5 million in 2024.